Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism

On the Role of Glucose-dependent Insulinotropic Polypeptide, GIP, in Postprandial Metabolism in Humans

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00999271

Enrollment

Registered

2009-10-21

Start date

2008-08-31

Completion date

2009-09-30

Last updated

2009-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Keywords

Glucose-dependent insulinotropic polypeptide, gastric emptying, appetite, energy intake, lipid metabolism

Brief summary

The aim of this proposal is to examine whether endogenous GIP and exogenous GIP alone and in combination with insulin affect gastric emptying (GE), appetite, energy intake, energy expenditure (EE) and plasma levels of triglycerides (TAG), free fatty acids FFA) and glycerol in man.

Interventions

OTHERIncretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)

two different dosages: * 0.8 pmol/kg/min * 1.5 pmol/kg/min for 300 minutes

Study design

Observational model

CASE_CONTROL

Eligibility

Sex/Gender

MALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Informed oral and written consent * Caucasians over the age of 18 years * Normal 75 g oral glucose tolerance test (OGTT) * Normal blood haemoglobin concentration * Normal plasma lipid profile

Exclusion criteria

* First-degree relatives with diabetes and familial hypertriglyceridemia

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026